Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 83 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer... MOST POPULAR EMA Adopts a Positive Opinion for a New Route of Administration... May 8, 2026 How Early Cancer Detection and Diagnosis Saved My Life Twice: A... December 27, 2023 Dame Deborah James: why do deeply personal stories resonate with us... May 24, 2022 What Are Biosimilars in Cancer Treatment? September 15, 2020 Load more HOT NEWS FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax... The Healing Power of Being Outdoors for People With Cancer John Travolta Supports Olivia Newton-John As She Battles Cancer Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy...
